MIV-150 + LNG ring
MZCL Combination IVR
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Vaginal Ring
-
Intended Duration:
- Short-Acting
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): Population Council, ProMed Pharma
Details
- API: Levonorgestrel, MIV-150, Zinc Acetate, Carrageenan
- Target: Progesterone Receptor
-
Mechanism of Action:
- Ovulation Inhibition
- Cervical Mucus Changes
- Endometrial Changes
- Anti-Microbial
- Inactive Materials: EVA, Silicone
- Regimen: Undetermined
- MPT: Potential MPT
Product Status
No additional publications, and information on the developer site suggests the development of a different MPT vaginal ring formulation
History
Prototype macaque MZCL IVRs have undergone preclinical testing.